Abstract
The success of scientific discovery in preclinical drug development is based on the different roles of exploration and confirmation in this process. Via simulations, we show that our systemic approach - based on a smallest effect size of interest - increases discovery rates compared to a p-value based approach while keeping animal numbers low. Based on our findings, we argue for a reconsideration of planning and conducting preclinical experiments.
Competing Interest Statement
The authors have declared no competing interest.
Copyright
The copyright holder for this preprint is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license.